SEC Form 4 · accession 0000899243-18-018520
Seres Therapeutics, Inc. · MCRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Roger Pomerantz
Officer — President and CEO · Director
Period of report
Jun 25, 2018
Accepted (ET)
Jun 27, 2018 · 9:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609809
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 25, 2018 | M | 16,288 | $0.71 | A | 255,056 | D | |
| Common StockF2 | Jun 25, 2018 | S | 26,752 | $9.2144 | D | 228,304 | D | |
| Common Stock | Jun 26, 2018 | M | 21,224 | $0.71 | A | 249,528 | D | |
| Common StockF3 | Jun 26, 2018 | S | 21,224 | $9.194 | D | 228,304 | D | |
| Common Stock | Jun 27, 2018 | M | 16,991 | $0.71 | A | 245,295 | D | |
| Common StockF4 | Jun 27, 2018 | S | 16,991 | $9.0288 | D | 228,304 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| STOCK OPTION (RIGHT TO BUY)F5 | $0.71 | Jun 25, 2018 | M | 16,288 | D | — | Aug 7, 2024 | COMMON STOCK | 16,288 | 895,153 | D |
| STOCK OPTION (RIGHT TO BUY)F5 | $0.71 | Jun 26, 2018 | M | 21,224 | D | — | Aug 7, 2024 | COMMON STOCK | 21,224 | 873,929 | D |
| STOCK OPTION (RIGHT TO BUY)F5 | $0.71 | Jun 27, 2018 | M | 16,991 | D | — | Aug 7, 2024 | COMMON STOCK | 16,991 | 856,938 | D |
Explanation of responses
- F1The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018.
- F2The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.08 to $9.52. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.365. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.16. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5The option vested as to 25% of the shares on June 1, 2015. The remainder of the shares have vested or will vest in 12 equal quarterly installments thereafter.